Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

PSMA

  • You have access
    Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria
    Stefano Fanti, Boris Hadaschik and Ken Herrmann
    Journal of Nuclear Medicine May 1, 2020, 61 (5) 678-682; DOI: https://doi.org/10.2967/jnumed.119.233817
  • You have access
    Response Prediction of 177Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase
    Hendrik Rathke, Tim Holland-Letz, Walter Mier, Paul Flechsig, Eleni Mavriopoulou, Manuel Röhrich, Klaus Kopka, Markus Hohenfellner, Frederik Lars Giesel, Uwe Haberkorn and Clemens Kratochwil
    Journal of Nuclear Medicine May 1, 2020, 61 (5) 689-695; DOI: https://doi.org/10.2967/jnumed.119.231431
  • You have access
    Evaluation of an Automated Module Synthesis and a Sterile Cold Kit–Based Preparation of 68Ga-PSMA-11 in Patients with Prostate Cancer
    Letizia Calderoni, Andrea Farolfi, Davide Pianori, Elisa Maietti, Veronica Cabitza, Alessandro Lambertini, Giacomo Ricci, Silvi Telo, Filippo Lodi, Paolo Castellucci and Stefano Fanti
    Journal of Nuclear Medicine May 1, 2020, 61 (5) 716-722; DOI: https://doi.org/10.2967/jnumed.119.231605
  • You have access
    Additional Local Therapy for Liver Metastases in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Systemic PSMA-Targeted Therapy
    Robert Seifert, Katharina Kessel, Martin Boegemann, Michael Köhler, Wolfgang Roll, Lars Stegger, Matthias Weckesser and Kambiz Rahbar
    Journal of Nuclear Medicine May 1, 2020, 61 (5) 723-728; DOI: https://doi.org/10.2967/jnumed.119.233429
  • Open Access
    Radiohybrid Ligands: A Novel Tracer Concept Exemplified by 18F- or 68Ga-Labeled rhPSMA Inhibitors
    Alexander Wurzer, Daniel Di Carlo, Alexander Schmidt, Roswitha Beck, Matthias Eiber, Markus Schwaiger and Hans-Jürgen Wester
    Journal of Nuclear Medicine May 1, 2020, 61 (5) 735-742; DOI: https://doi.org/10.2967/jnumed.119.234922
  • You have access
    Prostate-Specific Membrane Antigen PET/CT Combined with Sentinel Node Biopsy for Primary Lymph Node Staging in Prostate Cancer
    Florentien J. Hinsenveld, Esther M.K. Wit, Pim J. van Leeuwen, Oscar R. Brouwer, Maarten L. Donswijk, Corinne N. Tillier, Erik Vegt, Erik van Muilekom, Matthias N. van Oosterom, Fijs W.B. van Leeuwen and Henk G. van der Poel
    Journal of Nuclear Medicine April 1, 2020, 61 (4) 540-545; DOI: https://doi.org/10.2967/jnumed.119.232199
  • You have access
    Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine
    Lilja B. Solnes, Rudolf A. Werner, Krystyna M. Jones, Mohammad S. Sadaghiani, Christopher R. Bailey, Constantin Lapa, Martin G. Pomper and Steven P. Rowe
    Journal of Nuclear Medicine March 1, 2020, 61 (3) 311-318; DOI: https://doi.org/10.2967/jnumed.118.220665
  • You have access
    Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines
    Kelsey L. Pomykala, Johannes Czernin, Tristan R. Grogan, Wesley R. Armstrong, John Williams and Jeremie Calais
    Journal of Nuclear Medicine March 1, 2020, 61 (3) 405-411; DOI: https://doi.org/10.2967/jnumed.119.230318
  • You have access
    Prospective Comparison of PET Imaging with PSMA-Targeted 18F-DCFPyL Versus Na18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer
    Steven P. Rowe, Xin Li, Bruce J. Trock, Rudolf A. Werner, Sarah Frey, Michael DiGianvittorio, J. Keith Bleiler, Diane K. Reyes, Rehab Abdallah, Kenneth J. Pienta, Michael A. Gorin and Martin G. Pomper
    Journal of Nuclear Medicine February 1, 2020, 61 (2) 183-188; DOI: https://doi.org/10.2967/jnumed.119.227793
  • You have access
    Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?
    Isabel Rauscher, Wolfgang P. Fendler, Thomas A. Hope, Andrew Quon, Stephan G. Nekolla, Jeremie Calais, Antonia Richter, Bernhard Haller, Ken Herrmann, Wolfgang A. Weber, Johannes Czernin and Matthias Eiber
    Journal of Nuclear Medicine February 1, 2020, 61 (2) 189-193; DOI: https://doi.org/10.2967/jnumed.119.227207

Pages

  • Previous
  • Next
  • 1
  • …
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 14
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire